The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma


Por: Degenhardt, J, Tolkach, Y, Amin, MB, Mosiello, G, Baydar, DE, Gall, ECL, Dicola, J, Elhag, D, Frezza, C, Halbritter, J, Blanco, I, Jewett, MAS, Lattouf, JB, Lovitt, G, Lundgren, PO, Maher, ER, Mulders, P, Shuch, B, Hartmann, A and Mueller, RU

Publicada: 1 jul 2025 Ahead of Print: 1 abr 2025
Resumen:
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is caused by heterozygous germline variants in the fumarate hydratase (FH) gene. Inheritance follows an autosomal dominant pattern. Loss of FH confers a predisposition for various benign and malignant neoplasms, including cutaneous leiomyomas, uterine fibroids and FH-deficient renal cell carcinoma. While benign, cutaneous and uterine manifestations have a relevant impact on quality of life and risk for complications, the vast majority of FH-deficient RCCs exhibit an aggressive behaviour with invasive growth and the potential for early metastatic spread. Additionally, pathogenic germline FH variants have been associated with other neoplasms, such as adrenal gland and Leydig cell tumours. The aggressive behaviour of FH-deficient RCC challenges nephron-sparing resection strategies, as a wide margin is recommended. Even after early nephrectomy for surgical removal of FH-deficient renal cell carcinomas, there is a relevant risk for distant metastasis as well as the remainingpredisposition for de novo primary renal tumours in the other kidney. Active screening is central to HLRCC care since no preventative HLRCC-specific treatment exists. Vascular endothelial growth factor/epidermal growth factor receptor-directed treatment regimes, such as erlotinib/bevacizumab, demonstrate efficacy against HLRCC-associated RCC. This emphasizes the importance of establishing the correct diagnosis in HLRCC early on to guide therapeutic decisions. Morphologic criteria as well as specific immunohistochemical staining and molecular genetics allow the identification of FH-deficient RCC. Changes made in the recent 2022 World Health Organization classification impact the diagnosis of HLRCC in multiple ways. This commentary aims to discuss this impact and raise awareness among pathologists as well as clinicians involved in the care of patients with HLRCC. 10.1093/ndt/gfaf032 Video Abstract Watch the video abstract of this contribution at https://academic.oup.com/ndt/pages/author_videos gfaf032Media1 6371303830112

Filiaciones:
Degenhardt, J:
 Univ Cologne, Dept Internal Med 2, Cologne, Germany

Tolkach, Y:
 Univ Hosp Cologne, Inst Pathol, Cologne, Germany

Amin, MB:
 Univ Tennessee, Coll Med, Dept Pathol & Lab Med, Hlth Sci Ctr, Memphis, TN USA

 Univ Southern Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA

Mosiello, G:
 Bambino Gesu Childrens Hosp IRCCS, Div Pediat Urol Neurourol, Rome, Italy

Baydar, DE:
 Koc Univ, Sch Med, Dept Pathol, Istanbul, Turkiye

Gall, ECL:
 Univ Brest, Ctr Reference Malad Renales Hereditaires l'Enfant, UMR 1078, GGB ,CHU Brest, Brest, France

Dicola, J:
 HLRCC Fdn, Coralville, IA USA

Elhag, D:
 HLRCC Fdn, Coralville, IA USA

 John Stoddard Canc Ctr, Coralville, IA USA

Frezza, C:
 Univ Cologne, Fac Med, Cologne, Germany

 Univ Hosp Cologne, Inst Metabol Ageing, Cluster Excellence Cellular Stress Responses Aging, Cologne, Germany

 Univ Cologne, Inst Genet, Cluster Excellence Cellular Stress Responses Aging, Fac Math & Nat Sci, Cologne, Germany

Halbritter, J:
 Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany

:
 Hosp Germans Trias i Pujol, Dept Clin Genet, Badalona, Spain

Jewett, MAS:
 Int Kidney Canc Coalit, Utrecht, Netherlands

Lattouf, JB:
 Univ Montreal Hosp Ctr, Dept Surg Urol, Montreal, PQ, Canada

Lundgren, PO:
 Karolinska Univ Hosp, Dept Urol, Stockholm, Sweden

Maher, ER:
 Aston Univ, Aston Med Sch, Birmingham, England

 Birmingham Womens & Childrens NHS Fdn Trust, Birmingham, England

 Cambridge Univ Hosp NHS Fdn Trust, Dept Med Genet, Cambridge, England

Mulders, P:
 Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

Shuch, B:
 Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA

Hartmann, A:
 Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Fac Med, Bavaria, Germany

Mueller, RU:
 Univ Cologne, Dept Internal Med 2, Cologne, Germany

 Univ Cologne, Ctr Mol Med, Cologne, Germany
ISSN: 14602385





Nephrology Dialysis Transplantation
Editorial
Oxford University Press, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, Reino Unido
Tipo de documento: Review
Volumen: 40 Número: 7
Páginas: 1428-1432
WOS Id: 001463272800001
ID de PubMed: 39979023
imagen Green Submitted, Green Accepted, hybrid

MÉTRICAS